“April 2017 : Intensification of the Company’s international development with the appointment of a new CEO : Mrs Nawal Ouzren”
“Sensorion aims to become a major player in the development of inner ear disease treatments of and thus fulfill unmet medical needs”
"Our mission is to develop innovative and targeted treatments for inner ear diseases with vertigo, tinnitus, hearing loss"
" Sensorion, has received “French Tech Pass” certification, and thus joins an exclusive circle of innovative French technology companies with substantial development potential"

Technological know-how

Our expertise in the inner ear field and neurosciences are the strength of Sensorion. Our company, founded with French and European academics has gradually diversified its core competencies with suitable recruitments supported by a network of partners and key opinion leaders.

This organic growth and partnerships enable us to develop and continuously optimize the expertise which is our core business. We select and develop potential drugs selected from a de-risked pool of late pre-clinical stage, clinical stage or marketed compounds obtained either through partnerships, collaborations or publically available drug libraries.

Our team, our know-how and our technological platform are the key factors of Sensorion to succeed.